vimarsana.com
  1. Home
  2. Live Updates
  3. Secondary Progressive Multiple Sclerosis - Breaking News

Page 21 - Secondary Progressive Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MRI a Poor Disability Predictor in Secondary Progressive MS

MRI measures have a weak and variable link to disability in patients with secondary progressive multiple sclerosis, new research suggests. However, newer measures may better reflect outcomes.

E ann yehMarcusw kochUniversity of calgaryInternational cognitive assessmentNeuroinflammatory disorders programExpanded disability status scaleFoot walkNine hole peg testMultiple sclerosisSymbol digit modalities testMedscape medical newsSick childrenBrief international cognitive assessmentMultiple sclerosis msMultiple sclerosisMagnetic resonance imaging mri

High-Potency SPMS Meds Limit Relapses, But Not Disability Progression

High-Potency SPMS Meds Limit Relapses, But Not Disability Progression
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Tomas kalincikLow efficacy therapySecondary progressive multiple sclerosisஇரண்டாம் நிலை ப்ரோக்ரெஸிவ் பல ஸ்க்லரோசிஸ்

TLSA: Intranasal Foralumab in COVID-19

TLSA: Intranasal Foralumab in COVID-19
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

United kingdomJohn vandermostenKevin schutzTiziana life sciences corporate presentationTherapeutics advisory panelRegulatory affairsRegulatory affairs onWomen hospital harvard medical schoolTiziana life sciencesZacks small cap researchMetabolic drugs advisory committeeAdvisory committee meetingPatient expanded access programAnnual general meetingZacks small capKingdom calls

TLSA: Nasally-administered Foralumab Trial in SPMS Patient

By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT On May 25, 2021, Tiziana Life Sciences PLC (NASDAQ:TLSA ) (LSE:TILS) announced that it had initiated a trial through the Individual Patient Expanded Access Program (EAP) of foralumab in a Secondary Progressive Multiple Sclerosis (SPMS) patient. This follows a previous release in late March that first introduced the effort that was cleared under the EAP. The first.

John vandermostenMariusz skwarczynskiIstvan tothTiziana life sciences corporate presentationWomen hospital harvard medical schoolZacks small cap researchTiziana life sciencesMetabolic drugs advisory committeeAdvisory committee meetingPatient expanded access programIndividual patient expanded access programSecondary progressive multiple sclerosisHospital harvard medical schoolMultiple sclerosisProvention bioZacks small cap

Tiziana Life Sciences : Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program (Form 6-K)

Message : Required fields Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program ● The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses. ● Previous clinical studies in healthy volunteers and COVID-19 patients showed that nasally administered Foralumab is well-tolerated with no apparent severe adverse events (SAEs) when dosed for up to 10 consecutive days. Results from these studies showed strong anti-inflammatory effects of the treatment regimen.

United statesUnited kingdomKunwar shailubhaiHoward weinerGabriele cerroneTanuja chitnisHarvard medical schoolNasal administration of foralumabTiziana life sciencesProfessor of neurology at harvard medical schoolPatient expanded access programRedchip companies incTiziana life sciences announces initiationClinical trialSecondary progressive multiple sclerosisNasal administration

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.